Patents Represented by Attorney, Agent or Law Firm Emily M. Haliday
-
Patent number: 7776605Abstract: The invention provides among other things methods and kits based on assaying for cardiac troponin autoantibodies, either in conjunction with an assay for cardiac troponin and/or as an independent indicator of cardiac pathology, such as myocarditis, cardiomyopathy, and/or ischemic heart disease. Assay methods of the invention can be employed among other things to identify cardiac pathology, or risk thereof, in subjects who have an autoimmune disease or who are related to an individual with an autoimmune disease. In particular embodiments, the invention also provides a method of determining whether a subject having, or at risk for, a cardiac pathology is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention.Type: GrantFiled: October 26, 2006Date of Patent: August 17, 2010Assignee: Abbott LaboratoriesInventors: Phillip G. Mattingly, Maciej Adamczyk, Roy Jeffrey Brashear, Robert C. Doss
-
Patent number: 6818184Abstract: The invention provides methods and devices for detecting the presence of one or more target analytes in a sample employing a channel having affixed therein one or more binding partners for each target analyte. Assays are carried out by transporting the sample through the channel to each successive binding partner so that target analyte present in said sample binds to the corresponding binding partner. The sample is then transported beyond the binding partner(s), followed by detection of any target analyte bound to each binding partner. In one embodiment, binding efficiency is increased by the use of segmented transport, wherein a first bolus or bubble of a fluid that is immiscible with the sample precedes the sample during transport and a second bolus or bubble of a fluid that is immiscible with the sample follows the sample. Many configurations are possible for the device of the invention.Type: GrantFiled: April 17, 2003Date of Patent: November 16, 2004Assignee: The Regents of the University of CaliforniaInventors: Mack J. Fulwyler, Joe W. Gray
-
Patent number: 6806055Abstract: A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV isolates from the geographic region and selecting an HIV strain having gp120 a neutralizing epitope in the V2 or C4 domain which is common among isolates in the geographic region. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3, and C4 domains of gp120 are determined. At least two HIV isolates having different neutralizing epitopes in the V2, V3, or C4 domain are selected and used.to make the vaccine. The invention also provides a multivalent HIV gp120 subunit vaccine.Type: GrantFiled: September 27, 2001Date of Patent: October 19, 2004Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Gerald R. Nakamura
-
Patent number: 6716592Abstract: The diagnosis of diabetes based on the level or ratio of P- and A-type inositolphosphoglycans (IPGs) in a sample from a patient is disclosed.Type: GrantFiled: June 11, 1999Date of Patent: April 6, 2004Assignee: Rodaris Pharmaceuticals LimitedInventors: Thomas William Rademacher, Patricia McLean
-
Patent number: 6686334Abstract: The role of the &egr; isozyme of protein kinase C (“PKC&egr;”) in pain perception, particularly hyperalgesia, methods of lessening pain through administration of inhibitors of PKC&egr;, methods of identifying compounds that modulate pain, and pharmaceutical compositions comprising an inhibitor of PKC&egr; and PKC&egr;-independent analgesic agent are disclosed.Type: GrantFiled: January 4, 2002Date of Patent: February 3, 2004Assignee: Regents of the University of CaliforniaInventors: Robert O. Messing, Jon D. Levine
-
Patent number: 6610499Abstract: The invention provides methods and devices for detecting the presence of one or more target analytes in a sample employing a channel having affixed therein one or more binding partners for each target analyte. Assays are carried out by transporting the sample through the channel to each successive binding partner so that target analyte present in said sample binds to the corresponding binding partner. The sample is then transported beyond the binding partner(s), followed by detection of any target analyte bound to each binding partner. In one embodiment, binding efficiency is increased by the use of segmented transport, wherein a first bolus or bubble of a fluid that is immiscible with the sample precedes the sample during transport and a second bolus or bubble of a fluid that is immiscible with the sample follows the sample. Many configurations are possible for the device of the invention.Type: GrantFiled: August 31, 2000Date of Patent: August 26, 2003Assignee: The Regents of the University of CaliforniaInventors: Mack J. Fulwyler, Joe W. Gray
-
Patent number: 6605591Abstract: A method of treating an individual to increase the individual's bone mineral density (BMD) is disclosed. The method includes co-administering a calcitonin-like agent and a DHEA-like agent. Also disclosed are methods for potentiating the effect of treatment with a calcitonin-like agent on BMD and for increasing BMD in an individual being treated with DHEA, e.g., for treatment of systemic lupus erythematosus (SLE).Type: GrantFiled: November 10, 2000Date of Patent: August 12, 2003Assignee: Genelabs Technologies, Inc.Inventor: Kenneth E. Schwartz
-
Patent number: 6585979Abstract: Oligonucleotide sequences encoding gp120 polypeptides from breakthrough isolates of vaccine trials using MN-rgp120 and the encoded gp120 polypeptides are provided. Use of the gp120 polypeptides from one or more of the isolates in a subunit vaccine, usually together with MN-rgp120, can provide protection against HIV strains that are sufficiently different from the vaccine strain (e.g.; MN-rgp120) that the vaccine does not confer protection against those strains. Antibodies induced by the polypeptides are also provided.Type: GrantFiled: October 15, 1999Date of Patent: July 1, 2003Assignee: Genentech, Inc.Inventor: Phillip W. Berman
-
Patent number: 6552010Abstract: This invention provides a method of treating systemic lupus erythematosus (SLE) with (DHEA) and a related pharmaceutical product.Type: GrantFiled: November 10, 2000Date of Patent: April 22, 2003Assignee: Genelabs Technologies, Inc.Inventors: Kenneth E. Schwartz, Marc J. Gurwith
-
Patent number: 6534285Abstract: Diagnostic product and vaccine for Acquired Immuno-deficiency Syndrome (AIDS) and methods for making and using same, wherein viral polypeptide sequences from an AIDS associated retrovirus are expressed directly or as a fusion polypeptide in a prokaryotic or mammalian cell expression host to produce a diagnostic product which specifically binds complementary antibody produced by individuals afflicted with AIDS or a vaccine against AIDS which confers resistance to infection by AIDS associated retrovirus. The reverse transcriptase of an AIDS associated retrovirus is used separately or in a whole cell assay to identify compounds which selectively inhibit retroviral reverse transcriptase.Type: GrantFiled: April 12, 2000Date of Patent: March 18, 2003Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Daniel J. Capon, Laurence A. Lasky
-
Patent number: 6495330Abstract: The present invention relates to materials and methods for the diagnosis and treatment of pre-eclampsia, and more particularly to the role of P-type inositolphosphoglycans (IPGs) in the occurrence of pre-eclampsia. Methods of diagnosing pre-eclampsia by determining the level of P-type IPGs and uses of antagonists of P-type IPGs in the treatment of pre-eclampsia are disclosed, together with a method for screening for P-type IPG antagonists.Type: GrantFiled: June 4, 1999Date of Patent: December 17, 2002Assignee: Rodaris Pharmaceuticals LimitedInventors: Thomas William Rademacher, Patricia McLean
-
Patent number: 6465219Abstract: This invention provides novel methods for producing a plurality of polynucleotides prepared from a polynucleotide sample and the plurality of polynucleotides so produced. The plurality of polynucleotides is either substantially enriched in high-abundance polynucleotide sequences relative to the polynucleotide sample or substantially enriched in low-abundance polynucleotide sequences relative to the polynucleotide sample. Each of the polynucleotides in the plurality of polynucleotides includes a RNA promoter sequence and a universal primer site. The invention also provides kits useful in the methods of the invention and for using the pools of polynucleotides produced thereby. The polynucleotide pools are useful in a wide variety of applications, such as cloning, expression, and hybridization studies. Pools enriched in low-abundance polynucleotides are particularly useful in studies aimed at identifying important regulatory proteins.Type: GrantFiled: August 7, 2000Date of Patent: October 15, 2002Assignee: Genemed Biotechnologies, Inc.Inventor: York Yuan-Yuan Zhu
-
Patent number: 6417506Abstract: The invention relates to the fabrication and use of biosensors comprising a plurality of optical fibers each fiber having attached to its “sensor end” biological “binding partners” (molecules that specifically bind other molecules to form a binding complex such as antibody-antigen, lectin-carbohydrate, nucleic acid-nucleic acid, biotin-avidin, etc.). The biosensor preferably bears two or more different species of biological binding partner. The sensor is fabricated by providing a plurality of groups of optical fibers. Each group is treated as a batch to attach a different species of biological binding partner to the sensor ends of the fibers comprising that bundle. Each fiber, or group of fibers within a bundle, may be uniquely identified so that the fibers, or group of fibers, when later combined in an array of different fibers, can be discretely addressed. Fibers or groups of fibers are then selected and discretely separated from different bundles.Type: GrantFiled: August 17, 2000Date of Patent: July 9, 2002Assignees: The Regents of the University of California, Medical Research CouncilInventors: Daniel Pinkel, Joe Gray, Donna G. Albertson
-
Patent number: 6387638Abstract: The present invention provides heregulin variants that are capable of binding an ErbB receptor. Included in the invention are variants of human heregulins, and, in particular, variants of human heregulin-&bgr;1 having enhanced affinity for the ErbB-3 and ErbB-4 receptors. These variants include at least one amino acid substitution and can include further modifications. The invention also provides nucleic acid molecules encoding heregulin variants and related vectors, host cells, pharmaceutical compositions, and methods.Type: GrantFiled: July 17, 1998Date of Patent: May 14, 2002Assignee: Genentech, Inc.Inventors: Marcus D. Ballinger, Jennifer T. Jones, Wayne J. Fairbrother, Mark X. Sliwkowski, James A. Wells
-
Patent number: 6342157Abstract: The present invention provides a device for concentrating a blood fraction. The device includes an ultrafiltration unit connected to a fluid delivery system for delivering the blood fraction to be concentrated into the ultrafiltration unit. The device also includes a purge fluid delivery system for expelling concentrate from the ultrafiltration unit. In one embodiment, the device accommodates multiple cycles of concentration. A blood fraction concentration method is also provided. The device and method of the present invention are particularly useful for preparing a plasma concentrate suitable for use in a coagulum-based wound sealant.Type: GrantFiled: November 19, 1999Date of Patent: January 29, 2002Assignee: Interpore Orthopedics, Inc.Inventor: Andrew G. Hood, III
-
Patent number: 6335167Abstract: Disclosed are new methods comprising the use of in situ hybridization to detect abnormal nucleic acid sequence copy numbers in one or more genomes wherein repetitive sequences that bind to multiple loci in a reference chromosome spread are either substantially removed and/or their hybridization signals suppressed. The invention termed Comparative Genomic Hybridization (CGH) provides for methods of determining the relative number of copies of nucleic acid sequences in one or more subject genomes or portions thereof (for example, a tumor cell) as a function of the location of those sequences in a reference genome (for example, a normal human genome). The intensity(ies) of the signals from each labeled subject nucleic acid and/or the differences in the ratios between different signals from the labeled subject nucleic acid sequences are compared to determine the relative copy numbers of the nucleic acid sequences in the one or more subject genomes as a function of position along the reference chromosome spread.Type: GrantFiled: May 14, 1999Date of Patent: January 1, 2002Assignee: The Regents of the University of CaliforniaInventors: Daniel Pinkel, Joe W. Gray, Anne Kallioniemi, Ollie-Pekka Kallioniemi, Frederic Waldman, Masaru Sakamoto
-
Patent number: 6331404Abstract: A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV isolates from the geographic region and selecting an HIV strain having gp120 a neutralizing epitope in the V2 or C4-domain which is common among isolates in the geographic region. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3, and C4 domains of gp120 are determined. At least two HIV isolates having different neutralizing epitopes in the V2, V3, or C4 domain are selected and used to make the vaccine. The invention also provides a multivalent HIV gp120 subunit vaccine.Type: GrantFiled: January 27, 2000Date of Patent: December 18, 2001Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Gerald R. Nakamura
-
Patent number: 6303580Abstract: The present invention provides for an isolated A-type substance having a structure identical to an A-type substance obtained from human liver or placenta, which is a cyclical containing carbohydrate comprising Zn2+ and related compositions.Type: GrantFiled: June 4, 1999Date of Patent: October 16, 2001Assignee: Rademacher Group LimitedInventors: Thomas William Rademacher, Hugo Caro
-
Patent number: 6271204Abstract: The present invention provides for an isolated P-type substance having a structure identical to a P-type substance obtained from human liver or placenta, which is a cyclitol containing carbohydrate comprising Mn2+ and Zn2+ and related compositions.Type: GrantFiled: June 14, 1999Date of Patent: August 7, 2001Assignee: Rademacher Group LimitedInventors: Thomas William Rademacher, Hugo Caro
-
Patent number: 6214357Abstract: The present invention provides methods for using a killed malaria parasite or an extract thereof in the treatment of non-insulin dependent diabetes mellitus (NIDDM).Type: GrantFiled: November 30, 1999Date of Patent: April 10, 2001Assignee: Rademacher Group LimitedInventors: John Hugh Lyon Playfair, Khaled Elased, Joseph Brian De Souza